Royalty Pharma Expects 2025 Portfolio Receipts Of $2.975B-$3.125B (Prior $2.9B-$3.05B)

Benzinga · 05/08 11:23

Raised financial guidance for full year 2025 (excludes contribution from future transactions)

  • Royalty Pharma expects 2025 Portfolio Receipts to be between $2,975 million and $3,125 million, representing expected growth of 6% to 12%.
  • The company expects to update 2025 guidance for payments and operating and professional costs and interest paid after the closing of the internalization transaction, which is expected in the second quarter of 2025.